Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
https://www.gilead.com/Gilead Sciences, Inc is a California-based pharmaceutical company engaged in viral disease research and drug production. Founded in 1987, it existed for a long time through private investment and commissioned research. After the IPO, the company released several popular drugs and became an industry leader.
Now 90% of sales accounts for the US market. Company’s production facilities are located in California and New Jersey, as well as in a number of other countries - Ireland, Canada, and the Netherlands.
Statistics
According to data for 2021:
Shares and investments
The IPO, carried out in 1992, played a significant role in the growth and development of the corporation. Gilead Sciences shares were listed on one of the largest US exchanges, NASDAQ, under the ticker GILD. This allowed the company to attract $86 mn in revenue.
Now the corporation's shares are a component of several significant stock indices of the US market:
The company also regularly pays dividends, and against the backdrop of the pandemic and the associated crisis, they increased from $0.63 to $0.73 per share.
How can an individual buy Gilead Sciences shares?
We offer direct access to trading on NASDAQ, where you can invest and speculate not only in GILD stocks, but also in many other major US companies. To do this:
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
